MS patients may soon get a simpler shot option

NCT ID NCT07609719

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfied with the treatment. The goal is to offer a more convenient option for managing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab combined with recombinant human hyaluronidase (rHuPH20) given as a shot under the skin
What this could lead to: If it works, this could offer a more convenient way to control multiple sclerosis with fewer clinic visits.
What could go wrong: This is a small, early-phase study with no placebo group, so results may not apply broadly. Switching therapies could also cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Caribbean Center for Clinical Research
RECRUITING

Guaynabo, 00968, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.